

Date of preparation: 2021-11-30

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Mabion enters into an agreement for the supply of four bioreactors to the Company's manufacturing facility

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

The Management Board of Mabion S.A. (“Company”) hereby informs that on 30 November 2021, it entered into an agreement with Adolf Kühner AG with its registered office in Switzerland (“Supplier”) for the purchase of four bioreactors with a capacity of 2,500 litres each, together with ancillary services (“Agreement”).

Under the Agreement, the Supplier will produce and deliver to the Company four bioreactors as per the specification set forth in the Agreement, two of which will form part of a second manufacturing line and two others will be used to replace existing bioreactors as part of the Company's facility modernisation.

The Supplier will be responsible for commissioning and configuration of the equipment at the Company's manufacturing facility in Konstantynów Łódzki and for training the Company's staff. The ordered equipment is expected to meet both European and American GMP (Good Manufacturing Practice) requirements.

The procurement of the aforementioned bioreactors will allow the Company to double its current manufacturing capacity and is consistent with the Company's development plans, as announced by the Company in its current and periodic reports to date, including but not limited to Current Report no. 52/2021 of 8 October 2021. The increase in manufacturing capacity will first of all enable an increase in contract manufacturing of the COVID-19 vaccine candidate antigen for Novavax, Inc. and, together with the planned construction of a new plant equipped with additional bioreactors, will allow to ensure manufacturing capacity for the planned contract manufacturing services for further business partners, as well as for the future manufacturing of MabionCD20 drug after the successful completion of the registration procedure with the European Medicines Agency.

The Agreement's net value is EUR 2.3 million. The purchase of the equipment will be financed with the Company's own funds and forms part of the overall necessary investment expenditure of PLN 45-50 million, planned to be spent on process and analytical equipment to increase the manufacturing capacity at the existing facility. The assembly, installation, and commissioning of the equipment will be completed within 15 months from the date of the Agreement. The Company expects that the new bioreactors will be production-capable as of Q2 2023.